

# Vladimir Maisnar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8013193/publications.pdf>

Version: 2024-02-01

69  
papers

2,012  
citations

566801

15  
h-index

243296

44  
g-index

73  
all docs

73  
docs citations

73  
times ranked

2494  
citing authors

#	ARTICLE	IF	CITATIONS
1	Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. <i>Leukemia</i> , 2022, 36, 288-291.	3.3	23
2	Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice. <i>BMC Cancer</i> , 2021, 21, 73.	1.1	20
3	Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis. <i>Leukemia Research</i> , 2021, 104, 106576.	0.4	19
4	Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data. <i>European Journal of Haematology</i> , 2021, 107, 466-474.	1.1	1
5	Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. <i>Future Oncology</i> , 2021, 17, 2499-2512.	1.1	11
6	Urine immunofixation negativity is not necessary for complete response in intact immunoglobulin multiple myeloma: Retrospective real-world confirmation. <i>International Journal of Laboratory Hematology</i> , 2021, 43, e244-e247.	0.7	1
7	Identification of patients at high risk of secondary extramedullary multiple myeloma development. <i>British Journal of Haematology</i> , 2021, , .	1.2	8
8	Follow-up Analysis of Ixazomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Routine Clinical Practice. <i>Blood</i> , 2021, 138, 2716-2716.	0.6	1
9	Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in Czech Republic. <i>Blood</i> , 2021, 138, 4894-4894.	0.6	0
10	Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data. <i>European Journal of Health Economics</i> , 2020, 21, 219-233.	1.4	7
11	Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trial. <i>European Journal of Haematology</i> , 2020, 104, 443-458.	1.1	10
12	Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model. <i>British Journal of Haematology</i> , 2020, 190, 189-197.	1.2	13
13	Bortezomib retreatment is effective in relapsed multiple myeloma patients – real-life clinical practice data. <i>Neoplasma</i> , 2020, 67, 178-184.	0.7	2
14	Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma – analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies. <i>Neoplasma</i> , 2019, 66, 499-505.	0.7	4
15	Simplified novel prognostic score for real-life older adults with multiple myeloma – registry-based analysis. <i>Annals of Hematology</i> , 2019, 98, 951-962.	0.8	2
16	Overall Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) over Lenalidomide and Dexamethasone (RD) in RRMM Patients Treated in Routine Clinical Practice: Results from the Czech Registry of Monoclonal Gammopathies (RMG). <i>Blood</i> , 2019, 134, 3139-3139.	0.6	2
17	Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population. <i>Biomedical Papers of the Medical Faculty of the University Palacký&amp;#x0301;, Olomouc, Czechoslovakia</i> , 2019, 163, 279-283.	0.2	10
18	Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e219-e240.	0.2	16

#	ARTICLE	IF	CITATIONS
19	Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies. <i>Cancer Medicine</i> , 2018, 7, 4132-4145.	1.3	6
20	Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. <i>Journal of Hematology and Oncology</i> , 2018, 11, 49.	6.9	33
21	Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib+lenalidomide+dexamethasone versus placebo+lenalidomide+dexamethasone in relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 985-993.	2.0	41
22	A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance. <i>European Journal of Haematology</i> , 2017, 99, 80-90.	1.1	7
23	IgM myeloma: A multicenter retrospective study of 134 patients. <i>American Journal of Hematology</i> , 2017, 92, 746-751.	2.0	45
24	A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). <i>Leukemia</i> , 2017, 31, 107-114.	3.3	98
25	Epidemiology of Multiple Myeloma in the Czech Republic. <i>Klinicka Onkologie</i> , 2017, 30, 2S35-2S42.	0.1	15
26	Czech Registry of Monoclonal Gammopathies – Technical Solution, Data Collection and Visualisation. <i>Klinicka Onkologie</i> , 2017, 30, 2S43-2S50.	0.1	5
27	Asymptomatic and Treatment-requiring Multiple Myeloma – Data from the Czech Registry of Monoclonal Gammopathies. <i>Klinicka Onkologie</i> , 2017, 30, 2S51-2S59.	0.1	0
28	Whole Exome Sequencing of Aberrant Plasma Cells in a Patient with Multiple Myeloma Minimal Residual Disease. <i>Klinicka Onkologie</i> , 2017, 30, 2S75-2S80.	0.1	0
29	Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2016, 127, 1102-1108.	0.6	78
30	Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. <i>Blood</i> , 2016, 128, 1174-1180.	0.6	110
31	Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse. <i>European Journal of Haematology</i> , 2016, 96, 119-127.	1.1	8
32	Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. <i>Leukemia and Lymphoma</i> , 2016, 57, 2071-2076.	0.6	30
33	Comparative Effectiveness of Daratumumab Monotherapy Versus a Real-World Historical Control from the Czech Republic in Heavily Pretreated and Highly Refractory Multiple Myeloma Patients. <i>Blood</i> , 2016, 128, 3332-3332.	0.6	1
34	Multiple Myeloma R-ISS Prognostic Stratification System in Real Life Population. <i>Blood</i> , 2016, 128, 3333-3333.	0.6	3
35	Simple Prognostic Score for Evaluation of Elderly Multiple Myeloma Patients. <i>Blood</i> , 2016, 128, 5679-5679.	0.6	1
36	Improvement of Anaemia in Patients with Primary Myelofibrosis by Low-Dose Thalidomide and Prednisone. <i>Acta Medica (Hradec Kralove)</i> , 2016, 59, 50-53.	0.2	4

#	ARTICLE	IF	CITATIONS
37	IgM Myeloma: A Multicenter Retrospective Study of 159 Patients. <i>Blood</i> , 2016, 128, 3276-3276.	0.6	0
38	Immunoparesis in MGUS – Relationship of uninvolved immunoglobulin pair suppression and polyclonal immunoglobuline levels to MGUS risk categories. <i>Neoplasma</i> , 2015, 62, 827-832.	0.7	8
39	Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy. <i>PLoS ONE</i> , 2015, 10, e0123866.	1.1	32
40	Early Diagnosis of Multiple Myeloma - Project CRAB of Czech Myeloma Group(CMG). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e93.	0.2	0
41	Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 372, 142-152.	13.9	1,144
42	Registry of Monoclonal Gammopathies (RMG) in the Czech Republic. <i>Blood</i> , 2015, 126, 4514-4514.	0.6	11
43	Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391). <i>Blood</i> , 2015, 126, 731-731.	0.6	8
44	Stem Cell Mobilization after Various Induction Regimens in Patients with Multiple Myeloma. <i>Blood</i> , 2015, 126, 5433-5433.	0.6	0
45	Prediction of Progression of Smouldering into Therapy Requiring Multiple Myeloma By Easily Accessible Clinical Factors [in 527 Patients]. <i>Blood</i> , 2014, 124, 2071-2071.	0.6	9
46	Evaluation of Current Clinical Models for Risk of Progression from Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma or Related Malignancies in 2028 Persons Followed in the Czech Republic. <i>Blood</i> , 2014, 124, 3376-3376.	0.6	1
47	Early Diagnosis of Multiple Myeloma - Project CRAB of Czech Myeloma Group(CMG). <i>Blood</i> , 2014, 124, 5682-5682.	0.6	1
48	Subcutaneous and Intravenous Bortezomib in Multiple Myeloma Patients Has Similar Response Rates and Toxicity Profile with No Difference in the Incidence of Peripheral Neuropathy: Report of the Czech Myeloma Group. <i>Blood</i> , 2014, 124, 2117-2117.	0.6	0
49	10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group. <i>Leukemia Research</i> , 2013, 37, 1063-1069.	0.4	3
50	Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial. <i>Leukemia and Lymphoma</i> , 2012, 53, 920-927.	0.6	36
51	Successful radiotherapy treatment of lacrimal gland infiltration in patient with Sjögren's syndrome. <i>Bratislava Medical Journal</i> , 2012, 113, 249-250.	0.4	1
52	High-Dose Therapy and Autologous Stem Cell Transplantation for Multiple Myeloma: Analysis from Registry of Monoclonal Gammopathy of Czech Myeloma Group. <i>Blood</i> , 2012, 120, 4528-4528.	0.6	0
53	Association Study of Selected Genetic Polymorphisms and Occurrence of Venous Thromboembolism in Patients With Multiple Myeloma Who Were Treated With Thalidomide. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 414-420.	0.2	10
54	The problems of proteinuria measurement in urine with presence of Bence Jones protein. <i>Clinical Biochemistry</i> , 2011, 44, 403-405.	0.8	6

#	ARTICLE	IF	CITATIONS
55	Interlaboratory study of free monoclonal immunoglobulin light chain quantification. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 89-92.	1.4	7
56	Severe anemia caused by combination of autoimmune hemolysis, pure red cell aplasia and massive bone marrow infiltration in an elderly patient with chronic lymphocytic leukemia: Successful treatment with rituximab. <i>Leukemia Research</i> , 2010, 34, e140-e141.	0.4	1
57	Interference of IgM- $\lambda$ paraprotein with biuret-type assay for total serum protein quantification. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 235-6.	1.4	12
58	Diagnosis and surgical therapy of plasma cell neoplasia of the spine. <i>Neoplasma</i> , 2009, 56, 84-87.	0.7	7
59	High-dose chemotherapy followed by autologous stem cell transplantation changes prognosis of IgD multiple myeloma. <i>Bone Marrow Transplantation</i> , 2008, 41, 51-54.	1.3	19
60	Capillary immunotyping electrophoresis and high resolution two-dimensional electrophoresis for the detection of $\lambda$ 4-heavy chain disease. <i>Clinica Chimica Acta</i> , 2008, 389, 171-173.	0.5	4
61	The Czech National External Quality Assessment of monoclonal immunoglobulin in the period of 1996 - 2005. <i>Neoplasma</i> , 2008, 55, 61-4.	0.7	2
62	Solitary Extramedullary Plasmacytoma in the Oropharynx: Advantages of Intensity-Modulated Radiation Therapy. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, 434-437.	1.4	6
63	Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment. <i>European Journal of Haematology</i> , 2007, 79, 305-309.	1.1	9
64	Isotype class switching after transplantation in multiple myeloma. <i>Neoplasma</i> , 2007, 54, 225-8.	0.7	17
65	The significance of soluble CD138 in diagnosis of monoclonal gammopathies. <i>Neoplasma</i> , 2006, 53, 26-9.	0.7	6
66	Monoclonal gammopathies in a series of 1743 plasma donors. <i>Acta Medica (Hradec Kralove)</i> , 2006, 49, 119-21.	0.2	2
67	International Staging System required standardization of biochemical laboratory testing in multiple myeloma. <i>Neoplasma</i> , 2006, 53, 492-4.	0.7	9
68	The Frequency of Venous Thromboembolism in Women with F V Leiden in Heterozygous Form from the East Bohemia Region in Association with Pregnancy and Puerperium.. <i>Blood</i> , 2004, 104, 4006-4006.	0.6	0
69	Treatment of associated anemia in different hematological disorders with epoetin alpha. <i>Neoplasma</i> , 2004, 51, 379-84.	0.7	6